In This Section

Program

Please note that this meeting will take place as an in-person event in Los Angeles and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

[R] – Remote Presentation

Thursday, March 5

Friday, March 6

Saturday, March 7

SUNday, March 8

Thursday, March 5

REGISTRATION

3-7 p.m.

WELCOME AND OPENING Keynote

6-7 p.m.

  • 6 p.m. | Drugging RAS: What a long, strange trip it’s been  
    Channing Der, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Rising Star Lecture

6:45-7:15 p.m.

  • 6:45 p.m. | Response and resistance to RAS blockade in solid tumors and beyond
    Sandra Misale, Johns Hopkins University, Baltimore, Maryland

Opening Reception

7:30-9 p.m.

Friday, March 6

CONTINENTAL BREAKFAST AND NETWORKING ROUNDTABLES

7-8 a.m.

Plenary Session 1: RAS Biochemistry, Structure, and Mutations

8-10 a.m.

  • 8 a.m. | Piro Lito, Memorial Sloan Kettering Cancer Center, New York, New York
  • 8:30 a.m. | Mark Philips, New York University Perlmutter Cancer Center, New York, New York, USA

Short talks selected from proffered abstracts

BREAK

10-10:20 a.m.

Plenary Session 2: Effector Signaling

10:20 a.m.-12:20 p.m.

  • 10:20 a.m. | Determinants of KRAS effector signalling in pancreatic cancer – from tumor evolution to tumor-host interactions
    Dieter Saur, German Cancer Research Center and Technical University of Munich, Munich, Germany
  • 10:50 a.m. | Targeting the SHOC2-RAS interaction in RAS-mutant cancers
    Zachary Hauseman, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 

Additional speakers to be announced

Short talks selected from proffered abstracts

Lunch on Own

12:20-2:20 p.m.

Plenary Session 3: Colorectal Cancer: Therapeutic Challenges and Opportunities

2:20-4:20 p.m.

  • 2:20 p.m. | Rona Yaeger, Memorial Sloan Kettering Cancer Center, New York, New York
  • 2:50 p.m | Ryan Corcoran, Massachusetts General Hospital, Boston, Massachusetts  

Panel Discussion: RAS omics and Early Detection Advances

4:40-6:10 p.m.

  • 4:40 p.m. | Laura Wood, Johns Hopkins University, Baltimore, Maryland
  • 5 p.m. | Oncogenic Kras as a driver of the pancreatic cancer microenvironment
    Marina Pasca di Magliano, University of Michigan, Ann Arbor, Michigan

Short talks selected from proffered abstracts

Poster Session A and Reception

6:30-8:30 p.m.

Saturday, March 7

CONTINENTAL BREAKFAST AND Networking Roundtables           

7-8 a.m.

Keynote Lecture

8-8:45 a.m.

  • 8 a.m. | Targeting the oncogenic state of RAS: Lessons from tri-complex inhibitors
    Mallika Singh, Revolution Medicines, Redwood City, California

Plenary Session 4: RAS Clinical Trials and New Therapies

8:50-10:50 a.m.

  • 8:50 a.m. | Ferdinandos Skoulidis, MD Anderson Cancer Center, Houston, Texas
  • 9:20 a.m. | Eileen O’Reilly, Memorial Sloan Kettering Cancer Center, New York, New York

Break

10:50-11:10 a.m.

Plenary Session 5: Combinations

11:10 a.m.-1:10 p.m.

  • 11:10 a.m. | Targeting KRAS driven pancreatic cancer: Combination therapies   
    Mariano Barbacid, Spanish National Cancer Research Center (CNIO), Madrid, Spain 
  • 11:40 a.m. | Karen Cichowski, Brigham and Women’s Hospital, Boston, Massachusetts
  • 12:10 p.m. | David Tuveson, Cold Spring Harbor Laboratory, New York, New York

Short talks selected from proffered abstracts

Lunch on Own

1:10-3:10 p.m.

Plenary Session 6: Immunobiology and Immunotherapies for RAS Malignancies

3:10-5:10 p.m.

  • 3:10 p.m. | Philip Greenberg, Fred Hutchinson Cancer Center, Seattle, Washington
  • 3:40 p.m. | Elizabeth Jaffee, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 4:10 p.m. | Ron DePinho, MD Anderson Cancer Center, Houston, Texas

Short talks selected from proffered abstracts

Poster Session B and Reception

5:30-7:30 p.m.

Sunday, March 8

Continental Breakfast and Networking Roundtables

7-8 a.m.

Plenary Session 7: Resistance Mechanisms

8-10 a.m.

  • 8 a.m. | Signaling plasticity in pre-clinical models of resistance to KRAS inhibitors
    Chiara Ambrogio, Molecular Biotechnology Center (MBC), University of Torino, Torino, Italy
  • 8:30 a.m. | Boosting the immune system to counter resistance to KRAS inhibitory drugs in lung cancer 
    Julian Downward, The Francis Crick Institute, London, United Kingdom

Short talks selected from proffered abstracts

Break

10-10:20 a.m.

Plenary Session 8: Targeting NRAS, HRAS, and Rare KRAS Subtypes

10:20 a.m.-12:20 p.m.

  • 10:20 a.m. | Genetic determinants of sensitivity or resistance to pan-RAS(ON) inhibitors in NRAS-driven melanoma
    Martin McMahon, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah
  • 10:50 a.m. | Kevin Shannon, University of California, San Francisco, San Francisco, California
  • 11:20 a.m. | Kevin Haigis, Dana-Farber Cancer Institute, Boston, Massachusetts

Short talks selected from proffered abstracts

Closing Remarks

12:20 p.m.